All
Valeant outbids Merz for Obagi
April 8th 2013After Valeant Pharmaceuticals made a push to buy Obagi Medical Products for about $344 million in late March, Merz Pharma Group stepped up with an offer of about $384 million, but has since dropped its bid for the aesthetic skincare manufacturer, according to reports.
For some skin cancers, clinicians must consider less expensive options than Mohs surgery
April 1st 2013Although Mohs micrographic surgery represents the gold standard for treatment of many skin cancers, says an expert, healthcare reform dictates that dermatologists also consider less costly options when appropriate.
Staged excision techniques for lentigo maligna address challenges
April 1st 2013The many vagaries of lentigo maligna (LM) or melanoma in situ typically demand staged excision techniques for maximal margin control, according to an expert who spoke at the 71st annual American Academy of Dermatology conference.
Clinical research zeroes in on targeted therapies for skin cancers
March 18th 2013Continued research has led to new and exciting noninvasive therapies for basal cell carcinoma (BCC), lentigo maligna and malignant melanoma, offering some patients an alternative to surgery and/radiation treatment approaches.
Take-charge attitude toward marketing helps retain patients, increase referrals
March 18th 2013Physicians have a lot on their mind these days and, of course, some of it stems from the tenuous concerns about healthcare reform at a time when they are so busy trying to manage their schedules they don’t have time to come up for air.